The xCELLigence RTCA Cardio Instrument provides predictive information about cardiac safety during drug development by measuring cardiomyocyte beating under physiological conditions in cell culture. Through noninvasive, real-time monitoring in 96-well plates, the system detects drug-induced changes and simultaneously assesses cardiotoxicity and cell contractility. The system can additionally analyze both acute and long-term effects on a cell population.